Lazard Asset Management LLC Makes New $707,000 Investment in PROCEPT BioRobotics Corporation $PRCT

Lazard Asset Management LLC purchased a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 28,261 shares of the company’s stock, valued at approximately $707,000.

Other hedge funds also recently modified their holdings of the company. Baillie Gifford & Co. raised its stake in PROCEPT BioRobotics by 18.3% during the 4th quarter. Baillie Gifford & Co. now owns 1,015,978 shares of the company’s stock valued at $31,963,000 after purchasing an additional 157,147 shares during the last quarter. B. Metzler seel. Sohn & Co. AG acquired a new stake in PROCEPT BioRobotics in the 4th quarter worth $1,864,000. Pinnacle Associates Ltd. bought a new position in shares of PROCEPT BioRobotics during the 4th quarter worth about $3,876,000. DNB Asset Management AS increased its holdings in shares of PROCEPT BioRobotics by 213.9% during the 4th quarter. DNB Asset Management AS now owns 99,567 shares of the company’s stock worth $3,132,000 after purchasing an additional 67,848 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of PROCEPT BioRobotics by 69.8% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 174,739 shares of the company’s stock valued at $5,375,000 after buying an additional 71,832 shares during the last quarter. 89.46% of the stock is owned by institutional investors.

PROCEPT BioRobotics Price Performance

NASDAQ:PRCT opened at $19.34 on Thursday. The company has a 50-day moving average of $21.85 and a 200-day moving average of $24.89. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -9.97 and a beta of 0.89. PROCEPT BioRobotics Corporation has a 52 week low of $16.67 and a 52 week high of $47.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.51 and a current ratio of 6.73.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.10%. The business had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. During the same quarter last year, the firm posted ($0.35) earnings per share. PROCEPT BioRobotics’s revenue was up 19.3% on a year-over-year basis. As a group, equities research analysts anticipate that PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current fiscal year.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Second-quarter revenue rose 19.3% year over year to $94.5 million, exceeding analysts’ $92.77 million estimate. The result suggests continued demand for PROCEPT’s urology-focused robotic systems despite broader concerns about customer inventory. PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management forecast fiscal 2026 revenue of $390 million to $410 million, a range that broadly brackets the $397.2 million consensus estimate and may have eased concerns about a sharp near-term slowdown.
• Neutral Sentiment: The company reported an adjusted loss of $0.47 per share, narrowly missing the $0.46 consensus estimate and worsening from a $0.35 loss in the year-ago quarter. PROCEPT remains unprofitable, with analysts expecting a full-year loss. PROCEPT BioRobotics Reports Q2 Loss, Beats Revenue Estimates
• Negative Sentiment: Wells Fargo downgraded PROCEPT from “overweight” to “equal weight” and set a $19 price target, signaling limited upside at recent trading levels. Wells Fargo downgrade report
• Negative Sentiment: Multiple law firms publicized a securities-fraud class action covering investors who purchased PRCT shares from February 28, 2024, through February 25, 2026. The allegations include material misstatements about product demand, excess customer inventory, and late-quarter bulk discounts that may have overstated recurring-revenue trends. Investors seeking lead-plaintiff status generally face a September 22, 2026 deadline. Levi & Korsinsky PROCEPT class action alert

Analysts Set New Price Targets

PRCT has been the subject of several research reports. Truist Financial set a $21.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday. William Blair lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Wall Street Zen raised PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. UBS Group downgraded PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a research report on Tuesday, July 28th. Finally, Leerink Partners lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $31.00 to $29.00 in a report on Thursday, June 11th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $28.00.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.